CXD101 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of histone deacetylase (HDAC) enzymes, which play a crucial role in regulating gene expression. By inhibiting HDACs, CXD101 promotes the acetylation of histones, leading to the reactivation of tumor suppressor genes and the induction of apoptosis in cancer cells. This mechanism makes it a promising candidate for the treatment of various cancers, particularly hematological malignancies and solid tumors. Clinical trials are ongoing to evaluate its efficacy, safety, and potential as a standalone or combination therapy in cancer treatment regimens. Additionally, research is exploring its role in modulating the immune response, which could enhance its utility in immunotherapy approaches.